$RENB Cutting Edge AI Company GEDiCube and Cyclomi
Post# of 42150
Renovaro Biosciences Inc.
Renovaro Biosciences Inc.Renovaro Biosciences Inc.
Renovaro Biosciences Inc.
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.